3-Bromo-5-nitro-1H-pyrazolo[3,4-b]pyridine

Catalog No. :
ACNKFB723
CAS No. :
1186608-83-2
Molecular Formula :
C6H3BrN4O2
Molecular Weight :
243.02

IUPAC Name:3-bromo-5-nitro-1H-pyrazolo[3,4-b]pyridine

3-Bromo-5-nitro-1H-pyrazolo[3,4-b]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$52.00Login to see priceIn stockIn stock
5g97%$233.00Login to see priceIn stockIn stock
25g97%$867.00Login to see priceIn stockInquiry
100g97%$2682.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-Bromo-5-nitro-1H-pyrazolo[3,4-b]pyridine
IUPAC Name3-bromo-5-nitro-1H-pyrazolo[3,4-b]pyridine
MDL No.MFCD13193610
Molecular FormulaC6H3BrN4O2
Molecular Weight243.02
SMILESO=[N+](C1=CN=C(NN=C2Br)C2=C1)[O-]
InChI KeyKUKTUBBDMTVCMV-UHFFFAOYSA-N
SynonymKUKTUBBDMTVCMV-UHFFFAOYSA-N | CS-0044890 | SCHEMBL1496184 | 3-Bromo-5-nitropyrazolo[3,4-b]pyridine | SY111824 | AKOS015920177 | MFCD13193610 | A893059 | 3-bromo-5-nitro-2H-pyrazolo[3,4-b]pyridine | DTXSID20720955 | 1186608-83-2 | 3-Bromo-5-nitro-1H-pyrazo
CAS No.1186608-83-2
PubChem CID57345808

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACNKFB723 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACIQBJ923 route compound structure diagram
    ACIQBJ92363572-73-6 In Stock
  4. Then
  5. ACNKFB723 route product structure diagram
    ACNKFB7231186608-83-2 In Stock
Inquiry

2. ACNKFB723 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACIQBJ923 route compound structure diagram
    ACIQBJ92363572-73-6 In Stock
  2. Then
  3. ACNKFB723 route product structure diagram
    ACNKFB7231186608-83-2 In Stock
Inquiry

Comments (0)